Stride Post Latest News
Related Articles
The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Illumina P/E ratio is 43.82. it has decreased in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Illumina’s P/E ratio
What is Illumina P/E Ratio?
Illumina’s P/E ratio is 43.82, which represents a 53.23% decrease from the same period last year. their average P / E ratio is 95,2 and their 5-year average is 78.44.
What is Illumina Net EPS?
Illumina’s net earnings for the most recent quarter were 4.46 US dollars, which represents a 15.21% decrease from the same period last year.
Who are Illumina Competitors?
Based on Jika.io AI model, Agilent Technologies, IDEXX Laboratories, IQVIA Holdings, Laboratory Corporation of America Holdings, Lonza Group AG, Metropolis Healthcare, Thermo Fisher Scientific, Waters are considered to be Illumina’s competitors because the companies operate within the same industry as Illumina and they are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Illumina.
Who is Illumina’s Biggest competitor?
Illumina’s biggest competitor is Agilent Technologies, based on the Jika.io AI model. it has a similar market capitalization as Illumina in the industry, it dominates a similar share of the market as Illumina, and it provides and markets very similar services.
What industry is Illumina in?
Illumina is part of the diagnostics and research industry and the healthcare sector.
Illumina vs Agilent Technologies
Market Cap: Illumina’s Market Cap of 30695768064 is lower than Agilent Technologies Market Cap of 36197437440.
Average Volume: Illumina’s Average Volume of 1.374M is lower than Agilent Technologies Average Volume of 1.999M.
Beta: Illumina’s Beta of 1.0 is lower than Agilent Technologies Beta of 1.06.
Revenue: Illumina’s Revenue of 4.526B is lower than Agilent Technologies Revenue of 6.319B.
Net Income: Illumina’s Net Income of 762.0M is higher than Agilent Technologies Net Income of 1.21B.
Gross Profit: Illumina’s Gross Profit of 3.154B is lower than Agilent Technologies Gross Profit of 3.407B.
Ebitda: Illumina’s Ebitda of 1.196B is lower than Agilent Technologies Ebitda of 1.762B.
P/E Ratio: Illumina’s P/E Ratio of 42.02 is higher than Agilent Technologies P/E Ratio of 29.27.
P/S Ratio: Illumina’s P/S Ratio of 6.59 is higher than Agilent Technologies P/S Ratio of 5.55.
P/B Ratio: Illumina’s P/B Ratio of 2.82 is lower than Agilent Technologies P/B Ratio of 7.07.
P/FCF Ratio: Illumina’s P/FCF Ratio of 147.48 is lower than Agilent Technologies P/FCF Ratio of 34.28.
ROE: Illumina’s ROE of 0.07 is lower than Agilent Technologies ROE of 0.25.
ROA: Illumina’s ROA of 0.05 is lower than Agilent Technologies ROA of 0.12.
Return On Capital Employed: Illumina’s Return On Capital Employed of -0.01 is lower than Agilent Technologies Return On Capital Employed of 0.17.
Gross Profit Margin: Illumina’s Gross Profit Margin of 0.69 is higher than Agilent Technologies Gross Profit Margin of 0.54.
Assets (Total): Illumina’s Assets (Total) of 15.217B is higher than Agilent Technologies Assets (Total) of 10.705B.
Debt (Total): Illumina’s Debt (Total) of 2.54B is lower than Agilent Technologies Debt (Total) of 2.729B.
Shareholders Equity: Illumina’s Shareholders Equity of 10.74B is lower than Agilent Technologies Shareholders Equity of 5.389B.
Illumina vs IDEXX Laboratories
Market Cap: Illumina’s Market Cap of 30695768064 is lower than IDEXX Laboratories Market Cap of 31521181696.
Average Volume: Illumina’s Average Volume of 1.374M is lower than IDEXX Laboratories Average Volume of 717460.0.
Beta: Illumina’s Beta of 1.0 is lower than IDEXX Laboratories Beta of 1.11.
Revenue: Illumina’s Revenue of 4.526B is higher than IDEXX Laboratories Revenue of 3.215B.
Net Income: Illumina’s Net Income of 762.0M is higher than IDEXX Laboratories Net Income of 744.845M.
Gross Profit: Illumina’s Gross Profit of 3.154B is higher than IDEXX Laboratories Gross Profit of 1.889B.
Ebitda: Illumina’s Ebitda of 1.196B is higher than IDEXX Laboratories Ebitda of 1.037B.
P/E Ratio: Illumina’s P/E Ratio of 42.02 is lower than IDEXX Laboratories P/E Ratio of 43.08.
P/S Ratio: Illumina’s P/S Ratio of 6.59 is lower than IDEXX Laboratories P/S Ratio of 9.67.
P/B Ratio: Illumina’s P/B Ratio of 2.82 is lower than IDEXX Laboratories P/B Ratio of 49.5.
P/FCF Ratio: Illumina’s P/FCF Ratio of 147.48 is lower than IDEXX Laboratories P/FCF Ratio of 52.39.
ROE: Illumina’s ROE of 0.07 is lower than IDEXX Laboratories ROE of 1.04.
ROA: Illumina’s ROA of 0.05 is lower than IDEXX Laboratories ROA of 0.28.
Return On Capital Employed: Illumina’s Return On Capital Employed of -0.01 is lower than IDEXX Laboratories Return On Capital Employed of 0.58.
Gross Profit Margin: Illumina’s Gross Profit Margin of 0.69 is higher than IDEXX Laboratories Gross Profit Margin of 0.59.
Assets (Total): Illumina’s Assets (Total) of 15.217B is lower than IDEXX Laboratories Assets (Total) of 2.437B.
Debt (Total): Illumina’s Debt (Total) of 2.54B is higher than IDEXX Laboratories Debt (Total) of 1.031B.
Shareholders Equity: Illumina’s Shareholders Equity of 10.74B is lower than IDEXX Laboratories Shareholders Equity of 689.992M.
Illumina vs IQVIA Holdings
Market Cap: Illumina’s Market Cap of 30695768064 is lower than IQVIA Holdings Market Cap of 40884264960.
Average Volume: Illumina’s Average Volume of 1.374M is higher than IQVIA Holdings Average Volume of 1.165M.
Beta: Illumina’s Beta of 1.0 is lower than IQVIA Holdings Beta of 1.41.
Revenue: Illumina’s Revenue of 4.526B is higher than IQVIA Holdings Revenue of 13.874B.
Net Income: Illumina’s Net Income of 762.0M is lower than IQVIA Holdings Net Income of 966.0M.
Gross Profit: Illumina’s Gross Profit of 3.154B is lower than IQVIA Holdings Gross Profit of 4.641B.
Ebitda: Illumina’s Ebitda of 1.196B is lower than IQVIA Holdings Ebitda of 2.768B.
P/E Ratio: Illumina’s P/E Ratio of 42.02 is higher than IQVIA Holdings P/E Ratio of 38.85.
P/S Ratio: Illumina’s P/S Ratio of 6.59 is higher than IQVIA Holdings P/S Ratio of 2.92.
P/B Ratio: Illumina’s P/B Ratio of 2.82 is lower than IQVIA Holdings P/B Ratio of 6.93.
P/FCF Ratio: Illumina’s P/FCF Ratio of 147.48 is lower than IQVIA Holdings P/FCF Ratio of 21.43.
ROE: Illumina’s ROE of 0.07 is lower than IQVIA Holdings ROE of 0.18.
ROA: Illumina’s ROA of 0.05 is higher than IQVIA Holdings ROA of 0.04.
Return On Capital Employed: Illumina’s Return On Capital Employed of -0.01 is lower than IQVIA Holdings Return On Capital Employed of 0.08.
Gross Profit Margin: Illumina’s Gross Profit Margin of 0.69 is higher than IQVIA Holdings Gross Profit Margin of 0.34.
Assets (Total): Illumina’s Assets (Total) of 15.217B is lower than IQVIA Holdings Assets (Total) of 24.689B.
Debt (Total): Illumina’s Debt (Total) of 2.54B is higher than IQVIA Holdings Debt (Total) of 12.438B.
Shareholders Equity: Illumina’s Shareholders Equity of 10.74B is lower than IQVIA Holdings Shareholders Equity of 6.042B.
Illumina vs Laboratory Corporation of America Holdings
Market Cap: Illumina’s Market Cap of 30695768064 is higher than Laboratory Corporation of America Holdings Market Cap of 22607677440.
Average Volume: Illumina’s Average Volume of 1.374M is lower than Laboratory Corporation of America Holdings Average Volume of 880980.0.
Beta: Illumina’s Beta of 1.0 is lower than Laboratory Corporation of America Holdings Beta of 1.04.
Revenue: Illumina’s Revenue of 4.526B is higher than Laboratory Corporation of America Holdings Revenue of 16.121B.
Net Income: Illumina’s Net Income of 762.0M is higher than Laboratory Corporation of America Holdings Net Income of 2.377B.
Gross Profit: Illumina’s Gross Profit of 3.154B is lower than Laboratory Corporation of America Holdings Gross Profit of 5.624B.
Ebitda: Illumina’s Ebitda of 1.196B is lower than Laboratory Corporation of America Holdings Ebitda of 4.082B.
P/E Ratio: Illumina’s P/E Ratio of 42.02 is higher than Laboratory Corporation of America Holdings P/E Ratio of 11.19.
P/S Ratio: Illumina’s P/S Ratio of 6.59 is higher than Laboratory Corporation of America Holdings P/S Ratio of 1.47.
P/B Ratio: Illumina’s P/B Ratio of 2.82 is higher than Laboratory Corporation of America Holdings P/B Ratio of 2.17.
P/FCF Ratio: Illumina’s P/FCF Ratio of 147.48 is higher than Laboratory Corporation of America Holdings P/FCF Ratio of 12.73.
ROE: Illumina’s ROE of 0.07 is lower than Laboratory Corporation of America Holdings ROE of 0.2.
ROA: Illumina’s ROA of 0.05 is lower than Laboratory Corporation of America Holdings ROA of 0.1.
Return On Capital Employed: Illumina’s Return On Capital Employed of -0.01 is lower than Laboratory Corporation of America Holdings Return On Capital Employed of 0.16.
Gross Profit Margin: Illumina’s Gross Profit Margin of 0.69 is higher than Laboratory Corporation of America Holdings Gross Profit Margin of 0.33.
About Illumina
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments. the company provides instruments and consumables used in genetic analysis, genotyping and sequencing services, instrument service contracts, development and licensing agreements, as well as cancer detection testing services. its customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories and consumer genomics companies. the company markets and distributes its products directly to customers in North America, Europe, Latin America and Asia-Pacific, and sells through life science distributors in various markets in Europe, Asia-Pacific, Latin America, the Middle East and Africa. the company was founded in 1998 and is based in San Diego, California.
